Supplementary Figure S5 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Authors
Jo Lynne Rokita (ORCID: https://orcid.org/0000-0003-2171-3627)
John M. Maris (ORCID: https://orcid.org/0000-0002-8088-7929)
Mark Gerelus (ORCID: https://orcid.org/0000-0001-8986-4523)
Esther R. Berko (ORCID: https://orcid.org/0000-0001-7181-1378)
Supplementary Figure S5 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Jo Lynne Rokita, John M. Maris, Mark Gerelus, Esther R. Berko et al.
Topics
Neuroblastoma Research and Treatments
article
Supplementary Figure S5 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma
Jo Lynne Rokita, John M. Maris, Mark Gerelus, Esther R. Berko, Smita Matkar, Yaël P. Mossé, Gabriela M. Witek, Timothy Joseph Stuhlmiller, Gary L. Johnson, Kateryna Krytska, Joshua R. Kalna, Alvin Farrel, Colleen E. Casey, Denis O. Okumu, Michael P. East, Steven Pastor, Khushbu Patel, Anne Kennedy
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Supplementary Figure S5 from Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma — Jo Lynne Rokita, John M. Maris, et al. · (2025) | TGRS Research Map | TGRS